185 related articles for article (PubMed ID: 38542097)
1. PIM Kinases as Potential Biomarkers and Therapeutic Targets in Inflammatory Arthritides.
Assirelli E; Ciaffi J; Scorcu V; Naldi S; Brusi V; Mancarella L; Lisi L; Pignatti F; Ursini F; Neri S
Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542097
[TBL] [Abstract][Full Text] [Related]
2. Pim Kinases as Therapeutic Targets in Early Rheumatoid Arthritis.
Maney NJ; Lemos H; Barron-Millar B; Carey C; Herron I; Anderson AE; Mellor AL; Isaacs JD; Pratt AG
Arthritis Rheumatol; 2021 Oct; 73(10):1820-1830. PubMed ID: 33779060
[TBL] [Abstract][Full Text] [Related]
3. JAK inhibitors, psoriatic arthritis, and axial spondyloarthritis: a critical review of clinical trials.
Keeling S; Maksymowych WP
Expert Rev Clin Immunol; 2021 Jul; 17(7):701-715. PubMed ID: 33944642
[TBL] [Abstract][Full Text] [Related]
4. Is the C-reactive protein-to-albumin ratio the most remarkable simple inflammatory marker showing active disease in patients with axial spondyloarthritis, psoriatic arthritis, and rheumatoid arthritis?
Kaplan H; Cengiz G; Şaş S; Eldemir YÖ
Clin Rheumatol; 2023 Nov; 42(11):2959-2969. PubMed ID: 37470884
[TBL] [Abstract][Full Text] [Related]
5. Management of Axial Spondyloarthritis - Insights into Upadacitinib.
Braun J; Kiltz U; Baraliakos X
Drug Des Devel Ther; 2022; 16():3609-3620. PubMed ID: 36268520
[TBL] [Abstract][Full Text] [Related]
6. Drug survival of biologics and novel immunomodulators for rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, and psoriasis - A nationwide cohort study from the DANBIO and DERMBIO registries.
Egeberg A; Rosenø NAL; Aagaard D; Lørup EH; Nielsen ML; Nymand L; Kristensen LE; Thyssen JP; Thomsen SF; Cordtz RL; Loft N; Skov L; Bryld LE; Rasmussen MK; Højgaard P; Kristensen S; Dreyer L
Semin Arthritis Rheum; 2022 Apr; 53():151979. PubMed ID: 35183936
[TBL] [Abstract][Full Text] [Related]
7. Psoriatic arthritis, axial spondyloarthritis and rheumatoid arthritis in Norway: nationwide prevalence and use of biologic agents.
Kerola AM; Rollefstad S; Kazemi A; Wibetoe G; Sexton J; Mars N; Kauppi M; Kvien TK; Haavardsholm EA; Semb AG
Scand J Rheumatol; 2023 Jan; 52(1):42-50. PubMed ID: 35014920
[TBL] [Abstract][Full Text] [Related]
8. Transcription and translation are primary targets of Pim kinase inhibitor SGI-1776 in mantle cell lymphoma.
Yang Q; Chen LS; Neelapu SS; Miranda RN; Medeiros LJ; Gandhi V
Blood; 2012 Oct; 120(17):3491-500. PubMed ID: 22955922
[TBL] [Abstract][Full Text] [Related]
9. PIM kinases are essential for chronic lymphocytic leukemia cell survival (PIM2/3) and CXCR4-mediated microenvironmental interactions (PIM1).
Decker S; Finter J; Forde AJ; Kissel S; Schwaller J; Mack TS; Kuhn A; Gray N; Follo M; Jumaa H; Burger M; Zirlik K; Pfeifer D; Miduturu CV; Eibel H; Veelken H; Dierks C
Mol Cancer Ther; 2014 May; 13(5):1231-45. PubMed ID: 24659821
[TBL] [Abstract][Full Text] [Related]
10. PIM-1 kinase is a novel regulator of proinflammatory cytokine-mediated responses in rheumatoid arthritis fibroblast-like synoviocytes.
Ha YJ; Choi YS; Han DW; Kang EH; Yoo IS; Kim JH; Kang SW; Lee EY; Song YW; Lee YJ
Rheumatology (Oxford); 2019 Jan; 58(1):154-164. PubMed ID: 30204915
[TBL] [Abstract][Full Text] [Related]
11. Preclinical characterization of INCB053914, a novel pan-PIM kinase inhibitor, alone and in combination with anticancer agents, in models of hematologic malignancies.
Koblish H; Li YL; Shin N; Hall L; Wang Q; Wang K; Covington M; Marando C; Bowman K; Boer J; Burke K; Wynn R; Margulis A; Reuther GW; Lambert QT; Dostalik Roman V; Zhang K; Feng H; Xue CB; Diamond S; Hollis G; Yeleswaram S; Yao W; Huber R; Vaddi K; Scherle P
PLoS One; 2018; 13(6):e0199108. PubMed ID: 29927999
[TBL] [Abstract][Full Text] [Related]
12. A small-molecule inhibitor of PIM kinases as a potential treatment for urothelial carcinomas.
Foulks JM; Carpenter KJ; Luo B; Xu Y; Senina A; Nix R; Chan A; Clifford A; Wilkes M; Vollmer D; Brenning B; Merx S; Lai S; McCullar MV; Ho KK; Albertson DJ; Call LT; Bearss JJ; Tripp S; Liu T; Stephens BJ; Mollard A; Warner SL; Bearss DJ; Kanner SB
Neoplasia; 2014 May; 16(5):403-12. PubMed ID: 24953177
[TBL] [Abstract][Full Text] [Related]
13. Mechanism-based combinations with Pim kinase inhibitors in cancer treatments.
Yang Q; Chen LS; Gandhi V
Curr Pharm Des; 2014; 20(42):6670-81. PubMed ID: 25341939
[TBL] [Abstract][Full Text] [Related]
14. Genetic and Molecular Distinctions Between Axial Psoriatic Arthritis and Radiographic Axial Spondyloarthritis: Post Hoc Analyses from Four Phase 3 Clinical Trials.
Kavanaugh A; Baraliakos X; Gao S; Chen W; Sweet K; Chakravarty SD; Song Q; Shawi M; Rahman P
Adv Ther; 2023 May; 40(5):2439-2456. PubMed ID: 36995469
[TBL] [Abstract][Full Text] [Related]
15. Comprehensive Insights that Targeting PIM for Cancer Therapy: Prospects and Obstacles.
Chen L; Mao W; Ren C; Li J; Zhang J
J Med Chem; 2024 Jan; 67(1):38-64. PubMed ID: 38164076
[TBL] [Abstract][Full Text] [Related]
16. Effect of body mass index on treatment response of biologic/targeted-synthetic DMARDs in patients with rheumatoid arthritis, psoriatic arthritis or axial spondyloarthritis. A systematic review.
Gialouri CG; Pappa M; Evangelatos G; Nikiphorou E; Fragoulis GE
Autoimmun Rev; 2023 Jul; 22(7):103357. PubMed ID: 37150489
[TBL] [Abstract][Full Text] [Related]
17. 2-Thioxothiazolidin-4-one Analogs as Pan-PIM Kinase Inhibitors.
Yun Y; Hong VS; Jeong S; Choo H; Kim S; Lee J
Chem Pharm Bull (Tokyo); 2021; 69(9):854-861. PubMed ID: 34470949
[TBL] [Abstract][Full Text] [Related]
18. Proviral integration site for Moloney murine leukemia virus 1, but not phosphatidylinositol-3 kinase, is essential in the antiapoptotic signaling cascade initiated by IL-5 in eosinophils.
Andina N; Didichenko S; Schmidt-Mende J; Dahinden CA; Simon HU
J Allergy Clin Immunol; 2009 Mar; 123(3):603-11. PubMed ID: 19152965
[TBL] [Abstract][Full Text] [Related]
19. Insights into the Interaction Mechanisms of the Proviral Integration Site of Moloney Murine Leukemia Virus (Pim) Kinases with Pan-Pim Inhibitors PIM447 and AZD1208: A Molecular Dynamics Simulation and MM/GBSA Calculation Study.
Chen Q; Wang Y; Shi S; Li K; Zhang L; Gao J
Int J Mol Sci; 2019 Oct; 20(21):. PubMed ID: 31671637
[TBL] [Abstract][Full Text] [Related]
20. Risk of pre-eclampsia and impact of disease activity and antirheumatic treatment in women with rheumatoid arthritis, axial spondylarthritis and psoriatic arthritis: a collaborative matched cohort study from Sweden and Denmark.
Secher AEP; Granath F; Glintborg B; Rom A; Hetland ML; Hellgren K
RMD Open; 2022 Nov; 8(2):. PubMed ID: 36328400
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]